Distinguished in Actinic Keratosis

Claas T. Ulrich

Berlin, BE, DE 
Distinguished in Actinic Keratosis
Berlin, BE, DE 
OverviewLocationsClinical Research

Overview

Claas Ulrich practices in Berlin, Germany. Ulrich is rated as a Distinguished expert by MediFind in the treatment of Actinic Keratosis. Their top areas of expertise are Actinic Keratosis, Bowen's Disease, Basal Cell Skin Cancer, and Cerebrospinal Fluid Leak.

Their clinical research consists of co-authoring 68 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 20 articles in the study of Actinic Keratosis.

Locations

Berlin, BE, Germany
Other Locations
Kiel, SH, Germany
Hannover, NI, Germany
Mitte, BE 10117, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Completed
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drugs: Vemurafenib, Cobimetinib, Atezolizumab
Study Phase: Phase 2
A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
Enrollment Status: Completed
Publish Date: February 11, 2022
Intervention Type: Drug
Study Drug: Vismodegib
Study Phase: Phase 2
View 1 Less Clinical Trial

68 Total Publications

Does early discontinuation of topical 4% 5-fluorouracil affect lesion clearance for actinic keratosis? Results from a dose-ranging study.
Does early discontinuation of topical 4% 5-fluorouracil affect lesion clearance for actinic keratosis? Results from a dose-ranging study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 23, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ulrich's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile